Derailed by the pandemic, FDA offers CRISPR, Vertex drug program VIP status for its comeback play

CRISPR Therapeutics may have run into a hurdle for its clinical program to advance CTX001 in severe hemoglobinopathies, but the FDA is on record that it will do everything it can to get the drug back on track and headed to the finish line.